BRCA1 and familial pancreatic carcinoma: Poly (ADP-ribose) polymerase (PARP) inhibitors, for example, are used for BRCA1/2-positive breast, ovarian, and pancreatic cancer [38, 39] and have been FDA approved in the United States for castration-resistant ATM-deficient prostate cancer following a recent clinical trial [40].